191 related articles for article (PubMed ID: 29683973)
21. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
Gunturu KS; Yao X; Cong X; Thumar JR; Hochster HS; Stein SM; Lacy J
Med Oncol; 2013 Mar; 30(1):361. PubMed ID: 23271209
[TBL] [Abstract][Full Text] [Related]
22. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
Ghorani E; Wong HH; Hewitt C; Calder J; Corrie P; Basu B
Oncology; 2015; 89(5):281-7. PubMed ID: 26372905
[TBL] [Abstract][Full Text] [Related]
24. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Ko AH; LoConte N; Tempero MA; Walker EJ; Kate Kelley R; Lewis S; Chang WC; Kantoff E; Vannier MW; Catenacci DV; Venook AP; Kindler HL
Pancreas; 2016 Mar; 45(3):370-5. PubMed ID: 26390428
[TBL] [Abstract][Full Text] [Related]
25. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
[TBL] [Abstract][Full Text] [Related]
26. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer.
Keum J; Lee HS; Kang H; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Bang S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):651-659. PubMed ID: 32185483
[TBL] [Abstract][Full Text] [Related]
27. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
28. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
29. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.
Conroy T; Paillot B; François E; Bugat R; Jacob JH; Stein U; Nasca S; Metges JP; Rixe O; Michel P; Magherini E; Hua A; Deplanque G
J Clin Oncol; 2005 Feb; 23(6):1228-36. PubMed ID: 15718320
[TBL] [Abstract][Full Text] [Related]
30. The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
Conroy T; Gavoille C; Samalin E; Ychou M; Ducreux M
Curr Oncol Rep; 2013 Apr; 15(2):182-9. PubMed ID: 23341367
[TBL] [Abstract][Full Text] [Related]
31. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.
Wang ZQ; Zhang F; Deng T; Zhang L; Feng F; Wang FH; Wang W; Wang DS; Luo HY; Xu RH; Ba Y; Li YH
Cancer Commun (Lond); 2019 May; 39(1):26. PubMed ID: 31068222
[TBL] [Abstract][Full Text] [Related]
33. [FOLFIRINOX Combination Chemotherapy in Patients with Metastatic or Recurrent Pancreatic Cancer--A Single Institution Experience].
Takeda Y; Katsura Y; Ohmura Y; Morimoto Y; Ishida T; Motoyama Y; Ohneda Y; Sato Y; Kuwahara R; Murakami K; Naito A; Kagawa Y; Okishiro M; Takeno A; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2360-3. PubMed ID: 26805364
[TBL] [Abstract][Full Text] [Related]
34. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.
Boone BA; Steve J; Krasinskas AM; Zureikat AH; Lembersky BC; Gibson MK; Stoller RG; Zeh HJ; Bahary N
J Surg Oncol; 2013 Sep; 108(4):236-41. PubMed ID: 23955427
[TBL] [Abstract][Full Text] [Related]
35. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
[TBL] [Abstract][Full Text] [Related]
36. ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.
Strippoli A; Rossi S; Martini M; Basso M; D'Argento E; Schinzari G; Barile R; Cassano A; Barone C
Oncotarget; 2016 Jun; 7(23):35159-68. PubMed ID: 27147577
[TBL] [Abstract][Full Text] [Related]
37. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Lee JC; Kim JW; Ahn S; Kim HW; Lee J; Kim YH; Paik KH; Kim J; Hwang JH
Eur J Cancer; 2017 May; 76():125-133. PubMed ID: 28324747
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
40. FOLFIRINOX: from the ACCORD study to 2014.
Oikonomopoulos GM; Syrigos KN; Skoura E; Saif MW
JOP; 2014 Mar; 15(2):103-5. PubMed ID: 24618428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
